Literature DB >> 15851907

In vitro and in vivo: the story of nonoxynol 9.

Sharon L Hillier1, Thomas Moench, Robin Shattock, Roberta Black, Patricia Reichelderfer, Fulvia Veronese.   

Abstract

There is an urgent need to expand the range of interventions to prevent HIV transmission and acquisition, especially those that can be controlled by women. Microbicides, defined as antimicrobial products that can be applied topically for the prevention of HIV and other sexually transmitted infections, may offer one of the most promising preventive interventions, because they could be inexpensive, readily available, and widely acceptable. The first microbial product to be clinically evaluated contained Nonoxynol-9 (nonylpenoxypolyethoxyethanol [N-9]), a nonionic surfactant, as the active agent. This article presents a review of the in vitro, ex vivo, and animal model data on the safety of N-9 and a critical analysis of their predictive power based on the results of multiple safety and efficacy trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15851907     DOI: 10.1097/01.qai.0000159671.25950.74

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  72 in total

1.  In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.

Authors:  Youssef Gali; Olivier Delezay; Joachim Brouwers; Noura Addad; Patrick Augustijns; Thomas Bourlet; Hind Hamzeh-Cognasse; Kevin K Ariën; Bruno Pozzetto; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  Microbicides: topical prevention against HIV.

Authors:  Robin J Shattock; Zeda Rosenberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

Review 3.  Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions.

Authors:  Jennifer Barrila; Andrea L Radtke; Aurélie Crabbé; Shameema F Sarker; Melissa M Herbst-Kralovetz; C Mark Ott; Cheryl A Nickerson
Journal:  Nat Rev Microbiol       Date:  2010-11       Impact factor: 60.633

Review 4.  Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.

Authors:  Jessica L Adams; Angela D M Kashuba
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-04       Impact factor: 5.237

5.  An anti-HIV microbicide comes alive.

Authors:  Laurel A Lagenaur; Edward A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

Review 6.  Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis.

Authors:  Diana Finzi; Susan F Plaeger; Carl W Dieffenbach
Journal:  Clin Vaccine Immunol       Date:  2006-07

Review 7.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

Review 8.  Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.

Authors:  Andrea R Thurman; Sharon Anderson; Gustavo F Doncel
Journal:  Am J Reprod Immunol       Date:  2014-02-13       Impact factor: 3.886

9.  High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides.

Authors:  Kathleen L Vincent; Nigel Bourne; Brent A Bell; Gracie Vargas; Alai Tan; Daniel Cowan; Lawrence R Stanberry; Susan L Rosenthal; Massoud Motamedi
Journal:  Sex Transm Dis       Date:  2009-05       Impact factor: 2.830

10.  Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid.

Authors:  Deborah J Anderson; D'Nyce L Williams; Susan A Ballagh; Kurt Barnhart; Mitchell D Creinin; Daniel R Newman; Frederick P Bowman; Joseph A Politch; Ann C Duerr; Denise J Jamieson
Journal:  Am J Reprod Immunol       Date:  2009-02       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.